Phase II evaluation of AMSA in patients with metastatic lung cancer

W. C. Nichols, R. T. Eagan, S. Frytak, J. N. Ingle, E. T. Creagan, L. K. Kvols

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Fifty-four patients with metastatic lung cancer were treated with AMSA. Patients with a performance score of 0-1, no prior chemotherapy, and normal liver function received a dose of 35 mg/m 2/day iv for 3 days every 4 weeks; patients with a performance score of 2-3, any prior chemotherapy, or abnormal liver functions received a dose of 30 mg/m 2/day on the same schedule. Among 53 evaluable patients, responses were noted in one with adenocarcinoma and in two with squamous cell carcinoma (overall response rate, 6%). We conclude that AMSA has limited activity in lung cancer when used in this schedule except perhaps in previously untreated squamous cell carcinoma. Only a limited number of patients with large cell or small cell carcinoma were treated.

Original languageEnglish (US)
Pages (from-to)1383-1385
Number of pages3
JournalCancer Treatment Reports
Volume64
Issue number12
StatePublished - 1980
Externally publishedYes

Fingerprint

Amsacrine
Lung Neoplasms
Squamous Cell Carcinoma
Appointments and Schedules
Drug Therapy
Small Cell Carcinoma
Liver
Adenocarcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nichols, W. C., Eagan, R. T., Frytak, S., Ingle, J. N., Creagan, E. T., & Kvols, L. K. (1980). Phase II evaluation of AMSA in patients with metastatic lung cancer. Cancer Treatment Reports, 64(12), 1383-1385.

Phase II evaluation of AMSA in patients with metastatic lung cancer. / Nichols, W. C.; Eagan, R. T.; Frytak, S.; Ingle, J. N.; Creagan, E. T.; Kvols, L. K.

In: Cancer Treatment Reports, Vol. 64, No. 12, 1980, p. 1383-1385.

Research output: Contribution to journalArticle

Nichols, WC, Eagan, RT, Frytak, S, Ingle, JN, Creagan, ET & Kvols, LK 1980, 'Phase II evaluation of AMSA in patients with metastatic lung cancer', Cancer Treatment Reports, vol. 64, no. 12, pp. 1383-1385.
Nichols WC, Eagan RT, Frytak S, Ingle JN, Creagan ET, Kvols LK. Phase II evaluation of AMSA in patients with metastatic lung cancer. Cancer Treatment Reports. 1980;64(12):1383-1385.
Nichols, W. C. ; Eagan, R. T. ; Frytak, S. ; Ingle, J. N. ; Creagan, E. T. ; Kvols, L. K. / Phase II evaluation of AMSA in patients with metastatic lung cancer. In: Cancer Treatment Reports. 1980 ; Vol. 64, No. 12. pp. 1383-1385.
@article{120abc3490414d00ab481a20e76ca3a5,
title = "Phase II evaluation of AMSA in patients with metastatic lung cancer",
abstract = "Fifty-four patients with metastatic lung cancer were treated with AMSA. Patients with a performance score of 0-1, no prior chemotherapy, and normal liver function received a dose of 35 mg/m 2/day iv for 3 days every 4 weeks; patients with a performance score of 2-3, any prior chemotherapy, or abnormal liver functions received a dose of 30 mg/m 2/day on the same schedule. Among 53 evaluable patients, responses were noted in one with adenocarcinoma and in two with squamous cell carcinoma (overall response rate, 6{\%}). We conclude that AMSA has limited activity in lung cancer when used in this schedule except perhaps in previously untreated squamous cell carcinoma. Only a limited number of patients with large cell or small cell carcinoma were treated.",
author = "Nichols, {W. C.} and Eagan, {R. T.} and S. Frytak and Ingle, {J. N.} and Creagan, {E. T.} and Kvols, {L. K.}",
year = "1980",
language = "English (US)",
volume = "64",
pages = "1383--1385",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Phase II evaluation of AMSA in patients with metastatic lung cancer

AU - Nichols, W. C.

AU - Eagan, R. T.

AU - Frytak, S.

AU - Ingle, J. N.

AU - Creagan, E. T.

AU - Kvols, L. K.

PY - 1980

Y1 - 1980

N2 - Fifty-four patients with metastatic lung cancer were treated with AMSA. Patients with a performance score of 0-1, no prior chemotherapy, and normal liver function received a dose of 35 mg/m 2/day iv for 3 days every 4 weeks; patients with a performance score of 2-3, any prior chemotherapy, or abnormal liver functions received a dose of 30 mg/m 2/day on the same schedule. Among 53 evaluable patients, responses were noted in one with adenocarcinoma and in two with squamous cell carcinoma (overall response rate, 6%). We conclude that AMSA has limited activity in lung cancer when used in this schedule except perhaps in previously untreated squamous cell carcinoma. Only a limited number of patients with large cell or small cell carcinoma were treated.

AB - Fifty-four patients with metastatic lung cancer were treated with AMSA. Patients with a performance score of 0-1, no prior chemotherapy, and normal liver function received a dose of 35 mg/m 2/day iv for 3 days every 4 weeks; patients with a performance score of 2-3, any prior chemotherapy, or abnormal liver functions received a dose of 30 mg/m 2/day on the same schedule. Among 53 evaluable patients, responses were noted in one with adenocarcinoma and in two with squamous cell carcinoma (overall response rate, 6%). We conclude that AMSA has limited activity in lung cancer when used in this schedule except perhaps in previously untreated squamous cell carcinoma. Only a limited number of patients with large cell or small cell carcinoma were treated.

UR - http://www.scopus.com/inward/record.url?scp=0019301736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019301736&partnerID=8YFLogxK

M3 - Article

C2 - 6894104

AN - SCOPUS:0019301736

VL - 64

SP - 1383

EP - 1385

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 12

ER -